Regenerative medicine for spinal cord injury utilizing iPS cells

Osahiko Tsuji, Satoshi Nori, Yoshiomi Kobayashi, Kanehiro Fujiyoshi, Hideyuki Okano, Yoshiaki Toyama, Masaya Nakamura

Research output: Chapter in Book/Report/Conference proceedingChapter


Reports of functional recovery from spinal cord injury (SCI) after the transplantation of rat-fetus-derived neural stem/precursor cells (NS/PCs) and murine embryonic stem cells (ES cells) have raised great expectations for the successful clinical trial of stem cell transplantation therapy. However, the ethical issues concerning about destroying human embryos or fertilized oocytes to obtain such stem cells have been a major impediment to developing clinically useful stem cell sources and to use them in clinical applications. Recently, induced pluripotent stem cells (iPS cells), which can serve as a source of autologous cell transplantation, have been attracting a lot of attention as a clinically practical alternative to stem cells obtained directly from tissues. In this chapter, we outline the neural induction of murine and human iPS cells, their therapeutic efficacy in mouse and primate SCI models, and their safety in vivo.

Original languageEnglish
Title of host publicationNeuroprotection and Regeneration of the Spinal Cord
PublisherSpringer Japan
Number of pages17
ISBN (Electronic)9784431545026
ISBN (Print)4431545018, 9784431545019
Publication statusPublished - 2014 Nov 1


  • Cell transplantation
  • Induced pluripotent stem cells
  • Neural differentiation
  • Safety
  • Spinal cord injury

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Regenerative medicine for spinal cord injury utilizing iPS cells'. Together they form a unique fingerprint.

Cite this